All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Oneness Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

TAIWAN Taiwan

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825

Contact the Supplier

Lead Product(s): FB825

Therapeutic Area: Dermatology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Leo Pharma

Deal Size: $570.0 million Upfront Cash: $40.0 million

Deal Type: Licensing Agreement April 15, 2020

Details:

Oneness will be responsible for executing the Phase 2a study for Atopic Dermatitis in the United States and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China.